Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus

European Journal of Pharmacology

Volumn 569, Issue 3, 2007, Pages 204-211

  Riad, Alexander ^a   Du, Jing ^a   Stiehl, Sebastian ^b   Westermann, Dirk ^a   Mohr, Zarah ^a   Sobirey, Meike ^a   Doehner, Wolfram ^a   Adams, Volker ^b   Pauschinger, Matthias ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Adhesion molecule; Atorvastatin; Diabetes mellitus; Endothelial dysfunction; ERK; Inflammation; NF B; Oxidative stress

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DIABETES MELLITUS; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; LIMB; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HEPTANOIC ACIDS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHORYLATION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; VASODILATION;

EID: 34547635035     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.04.065     Document Type: Article

References (43)

1. Adams V., Linke A., Krankel N., Erbs S., Gielen S., Mobius-Winkler S., Gummert J.F., Mohr F.W., Schuler G., and Hambrecht R. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 111 (2005) 555-562
2. Alp N.J., Mussa S., Khoo J., Cai S., Guzik T., Jefferson A., Goh N., Rockett K.A., and Channon K.M. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Invest. 112 (2003) 725-735
3. Angulo J., Rodriguez-Manas L., Peiro C., Neira M., Marin J., and Sanchez-Ferrer C.F. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 358 (1998) 529-537
4. Baldwin Jr. A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14 (1996) 649-683
5. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
6. Bedard K., and Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87 (2007) 245-313
7. Bellosta S., Ferri N., Arnaboldi L., Bernini F., Paoletti R., and Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 23 Suppl 2 (2000) B72-B78
8. Bowie A., and O'Neill L.A. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 59 (2000) 13-23
9. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., and Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
10. De Vriese A.S., Verbeuren T.J., Van de Voorde J., Lameire N.H., and Vanhoutte P.M. Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130 (2000) 963-974
11. Delbosc S., Morena M., Djouad F., Ledoucen C., Descomps B., and Cristol J.P. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J. Cardiovasc. Pharmacol. 40 (2002) 611-617
12. Dorenkamp M., Riad A., Stiehl S., Spillmann F., Westermann D., Du J., Pauschinger M., Noutsias M., Adams V., Schultheiss H.P., and Tschope C. Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism. Eur. J. Pharmacol. 520 (2005) 179-187
13. Fasching P., Veitl M., Rohac M., Streli C., Schneider B., Waldhausl W., and Wagner O.F. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81 (1996) 4313-4317
14. Ganz P., and Vita J.A. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 108 (2003) 2049-2053
15. Hawiger J. Innate immunity and inflammation: a transcriptional paradigm. Immunol. Res. 23 (2001) 99-109
16. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 87 (2000) 179-183
17. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., and Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 (1993) 2510-2516
18. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
19. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., Manes C., Fischer D., de Groot K., Fliser D., Fauler G., Marz W., and Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
20. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352 (2005) 1425-1435
21. Laufs U., and Liao J.K. Targeting Rho in cardiovascular disease. Circ. Res. 87 (2000) 526-528
22. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., and Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z. Kardiol. 93 (2004) 103-108
23. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
24. Libby P., Nathan D.M., Abraham K., Brunzell J.D., Fradkin J.E., Haffner S.M., Hsueh W., Rewers M., Roberts B.T., Savage P.J., Skarlatos S., Wassef M., and Rabadan-Diehl C. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111 (2005) 3489-3493
25. Marfella R., Esposito K., Giunta R., Coppola G., De Angelis L., Farzati B., Paolisso G., and Giugliano D. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 101 (2000) 2247-2251
26. Nishida S., Matsuoka H., Tsubaki M., Tanimori Y., Yanae M., Fujii Y., and Iwaki M. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Mol. Cell. Biochem. 269 (2005) 109-114
27. Park J.H., and Levitt L. Overexpression of mitogen-activated protein kinase (ERK1) enhances T-cell cytokine gene expression: role of AP1, NF-AT, and NF-KB. Blood 82 (1993) 2470-2477
28. Planavila A., Laguna J.C., and Vazquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim. Biophys. Acta 1687 (2005) 76-83
29. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., and Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97 (1996) 1916-1923
30. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., and Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104 (2001) 1767-1772
31. Springer T.A. Adhesion receptors of the immune system. Nature 346 (1990) 425-434
32. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004) 1381-1478
33. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1712-1729
34. Targonski P.V., Bonetti P.O., Pumper G.M., Higano S.T., Holmes Jr. D.R., and Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107 (2003) 2805-2809
35. Tschope C., Walther T., Escher F., Spillmann F., Du J., Altmann C., Schimke I., Bader M., Sanchez-Ferrer C.F., Schultheiss H.P., and Noutsias M. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy. FASEB J. 19 (2005) 2057-2059
36. Vikramadithyan R.K., Hu Y., Noh H.L., Liang C.P., Hallam K., Tall A.R., Ramasamy R., and Goldberg I.J. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 115 (2005) 2434-2443
37. Wang H.R., Li J.J., Huang C.X., and Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin. Chim. Acta 353 (2005) 53-60
38. Wang J., Song Y., Elsherif L., Song Z., Zhou G., Prabhu S.D., Saari J.T., and Cai L. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113 (2006) 544-554
39. Werner N., Nickenig G., and Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 97 (2002) 105-116
40. West I.C. Radicals and oxidative stress in diabetes. Diabet. Med. 17 (2000) 171-180
41. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
42. Xenos E.S., Stevens S.L., Freeman M.B., Cassada D.C., and Goldman M.H. Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells. Ann. Vasc. Surg. 19 (2005) 386-392
43. Zhou M.S., Jaimes E.A., and Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 44 (2004) 186-190